Back to Journals » Advances in Genomics and Genetics » Volume 2

Tuberous sclerosis complex: genetic basis and management strategies

Authors Tsai V, Crino PB

Received 19 October 2011

Accepted for publication 4 November 2011

Published 15 February 2012 Volume 2012:2 Pages 19—31

DOI https://doi.org/10.2147/AGG.S19837

Review by Single-blind

Peer reviewer comments 3

Victoria Tsai, Peter B Crino

PENN Epilepsy Center, PENN Tuberous Sclerosis Clinic, Department of Neurology and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that results from mutations in the TSC1 or TSC2 genes. TSC is a multisystem hamartoma syndrome with manifestations in the brain, heart, lungs, kidney, skin, and eyes. Neurologically, TSC patients may exhibit severe epilepsy, cognitive disabilities, and autism spectrum disorders. Many TSC patients also present with renal angiomyolipomas, polycystic kidney disease, skin lesions, and lymphangiomyomatosis. TSC1 and TSC2 proteins form a heterodimeric complex that serves to inhibit mammalian target of rapamycin (mTOR) signaling pathway through Ras homolog enriched in brain (Rheb). TSC1 and TSC2 receive activating or inhibitory signals from multiple inputs including growth factors, insulin signaling, energy and amino acid levels, and proinflammatory pathways, which are then integrated to regulate the activity of the mTOR pathway. mTOR signaling plays a critical role in regulating cell growth, transcription, translation, and autophagy. Animal models have shed light on certain features of TSC, but failed to recapitulate the disease completely and currently further research is under way to better understand this devastating disorder. Clinical trials with mTOR inhibitors have shown promising results for some features of TSC, but further research needs to be conducted to establish full indications for therapeutic treatment.

Keywords: tuberous sclerosis complex, TSC, TSC1, TSC2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Genome-wide association studies in asthma: progress and pitfalls

March ME, Sleiman PMA, Hakonarson H

Advances in Genomics and Genetics 2015, 5:107-119

Published Date: 30 January 2015

Human RECQ helicases: roles in cancer, aging, and inherited disease

Sidorova JM, Monnat Jr RJ

Advances in Genomics and Genetics 2015, 5:19-33

Published Date: 29 December 2014

Whole exome sequencing for cancer – is there evidence of clinical utility?

Malhotra A, Levine S, Allingham-Hawkins D

Advances in Genomics and Genetics 2014, 4:115-128

Published Date: 22 August 2014

Epigenetics and stroke risk – beyond the static DNA code

Matouk CC, Turgeon PJ, Marsden PA

Advances in Genomics and Genetics 2012, 2:67-84

Published Date: 16 October 2012

Erratum

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:49-50

Published Date: 3 August 2012

The genomics and genetics of endometrial cancer

O'Hara AJ, Bell DW

Advances in Genomics and Genetics 2012, 2:33-47

Published Date: 6 March 2012

Treatment of patients with von Willebrand disease

Tuohy E, Litt E, Alikhan R

Journal of Blood Medicine 2011, 2:49-57

Published Date: 20 April 2011